Overview

Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company